Abivax SA Sponsored ADR $ABVX Shares Purchased by Eversept Partners LP

Eversept Partners LP raised its position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 42.0% in the first quarter, HoldingsChannel reports. The fund owned 934,423 shares of the company’s stock after acquiring an additional 276,589 shares during the period. Abivax accounts for approximately 5.5% of Eversept Partners LP’s investment portfolio, making the stock its 2nd largest holding. Eversept Partners LP’s holdings in Abivax were worth $104,048,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ABVX. GHP Investment Advisors Inc. boosted its stake in Abivax by 155.6% in the 1st quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock valued at $26,000 after purchasing an additional 140 shares during the period. WPG Advisers LLC lifted its holdings in shares of Abivax by 125.9% during the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after buying an additional 253 shares in the last quarter. Assetmark Inc. boosted its position in shares of Abivax by 41.5% in the first quarter. Assetmark Inc. now owns 886 shares of the company’s stock valued at $99,000 after acquiring an additional 260 shares during the period. SmartHarvest Portfolios LLC grew its stake in shares of Abivax by 11.6% in the first quarter. SmartHarvest Portfolios LLC now owns 2,696 shares of the company’s stock valued at $300,000 after acquiring an additional 280 shares in the last quarter. Finally, Personal CFO Solutions LLC grew its stake in shares of Abivax by 10.5% in the first quarter. Personal CFO Solutions LLC now owns 3,027 shares of the company’s stock valued at $337,000 after acquiring an additional 288 shares in the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on ABVX shares. Truist Financial lifted their price objective on shares of Abivax from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a report on Friday, July 17th. Jefferies Financial Group upgraded shares of Abivax from a “hold” rating to a “buy” rating and lifted their price target for the company from $108.00 to $158.00 in a research report on Tuesday, June 30th. Citizens Jmp reiterated a “market outperform” rating and issued a $187.00 price target on shares of Abivax in a research note on Wednesday, July 1st. Finally, Piper Sandler boosted their price target on Abivax from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $156.50.

Abivax Stock Up 1.8%

ABVX stock opened at $128.00 on Tuesday. Abivax SA Sponsored ADR has a 52 week low of $65.67 and a 52 week high of $148.83. The business has a 50-day simple moving average of $118.28 and a 200 day simple moving average of $118.28. The company has a market cap of $11.16 billion, a PE ratio of -24.57 and a beta of 0.87.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million for the quarter, compared to analyst estimates of $0.40 million. On average, analysts anticipate that Abivax SA Sponsored ADR will post -3.4 EPS for the current fiscal year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.